LAURUSLABS

Laurus Labs, a prominent player in the Pharmaceuticals & Drugs industry, Key highlights from Laurus Labs' latest results include record net sales of Rs 1,720.30 crore and a remarkable operating profit to interest ratio of 7.46 times. The company also reported a net profit after tax of Rs 233.67 crore, showcasing a robust growth trajectory. With an earnings per share (EPS) of Rs 4.33, Laurus Labs demonstrates strong profitability. Despite a low debtors turnover ratio of 2.77 times, the overall financial health of Laurus Labs remains very positive. The stock is currently priced at Rs 616.15, with a 52-week high of Rs 660.90. Over the past year, Laurus Labs has outperformed the market with a return of 38.96%, significantly exceeding the BSE 500's 4.97% return. This performance underscores the company's strong market position and operational efficiency.